ARVO Annual Meeting
May 3-7, 2026
Denver, USA
https://www.arvo.org/annual-meeting
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Downloads
Upcoming
Events
BIO International Convention
June 22-25, 2026
San Diego, USA
https://convention.bio.org/
CRS (Controlled Release Society) Annual Meeting
July 6-9, 2026
Lisbon, Portugal
https://www.controlledreleasesociety.org/events/crs-2026-annual-meeting-exposition
CPHI South East Asia
July 8-10, 2026
Bangkok, Thailand
https://www.cphi.com/sea/en/attend/attend/why-attend.html
CPHI Milan
October 6-8, 2026
Milan, Italy
https://www.cphi.com/europe/en/exhibit/book-your-stand-milan.html
PODD – Partnership Opportunities in Drug Delivery
October 29-30, 2026
Boston, USA
https://poddconference.com/
BIO-Europe
November 9-11, 2026
Cologne, Germany
https://informaconnect.com/bioeurope/
Past
Events
Archive
AT Uro Congress
May 22-24, 2025
Vienna, Austria
International Partnering in Life-Sciences Society (IPLS)
September 29 – October 1, 2025
Berlin, Germany
https://ipls.online/events/
CPHI Frankfurt
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
PharmaSynergyRx
February 5-6, 2026
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2026/
EuroPLX
March 2-3, 2026
Lisbon, Portugal
https://www.raucon.com/euro-plx/euro-p-l-x-90
BIO-Europe Spring
March 23-25, 2026
Lisbon, Portugal
https://informaconnect.com/bioeurope-spring/
DCAT Week
March 23-26, 2026
New York City, USA
https://dcatweek.org/
PBP World Meeting
March 23-26, 2026
Prague, Czech Republic
https://worldmeeting.org/
analytica
March 24-27, 2026
Munich, Germany
https://analytica.de/de/muenchen/
Latest
News
AMW GmbH from Warngau continues to grow and establishes an advisory board
More than 100 people are now employed at the pharmaceutical plant in Warngau. In addition to the implants Goserelin and Leuprorelin and the patches Buprenorphin and Rivastigmine, the specialty pharmaceutical company developed a generic version of MSD’s Nuvaring contraceptive ring to market maturity. AMW is thus setting new standards in contraception. In order to improve its scientific and technical position, AMW has established an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.
read moreBrussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau
The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.
read moreEndomedica GmbH, our wholly owned subsidiary based in Halle, was able to present itself to a wide audience including well-known pharmaceutical companies and investors from the fields of biotechnology and medical technology at the Health Innovation Summit on 11.7.2017.
The event took place simultaneously as a webinar in Munich, Tokyo and Silicon Valley and allowed discussion rounds after the presentation.
read moreOn 22 June 2017, the AMW received a high visit from the Bavarian Minister of Economic Affairs and Deputy Prime Minister of the Free State of Bavaria.
Within this framework, the pharmaceutical plant was able to present itself as the largest training company in Warngau.
read moreSpecialty pharmaceutical company AMW takes big steps
Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialist pharmaceutical company with bright prospects. The company develops and distributes transdermal systems, i.e. active ingredients that enter the body through the skin, as well as implants loaded with highly effective active ingredients, which release their active ingredient evenly to the body for months and dissolve completely. AMW is supported by well-known investors. In a recent financing round to finance growth, investors reaffirmed their commitment to AMW and contributed a further six million euros.
read more